Pharming Group NV (PHAR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $891.80M
Last updated: Nov 17, 2026 at 11:03 AM ET
Pharming Group NV (PHAR) Financials: Revenue, Profit and Cash Flow
Pharming Group NV reported revenue of $376.13M for the fiscal year ended Dec 31, 2025, up 26.6% from the year before. That year, net income was $2.85M with a net margin of 0.8%, operating cash flow was $54.71M and free cash flow was $53.95M. The quarter ended Sep 30, 2026 had revenue of $117.56M and net income of $22.43M.
Revenue and Margins
The operating margin was 5.6% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $16.69M, a compound annual rate of 41.4%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $376.13M | +26.6% | 87.9% | 5.6% | 0.8% |
| Dec 2024 | $297.20M | +21.1% | 88.1% | -1.2% | -4.0% |
| Dec 2023 | $245.32M | +19.3% | 89.7% | -9.1% | -4.3% |
| Dec 2022 | $205.62M | +3.4% | 91.5% | 4.8% | 6.7% |
| Dec 2021 | $198.87M | -6.3% | 89.4% | 9.6% | 8.0% |
| Dec 2020 | $212.17M | +12.0% | 88.9% | 35.9% | 17.8% |
| Dec 2019 | $189.39M | +22.5% | 87.4% | 36.0% | 21.4% |
| Dec 2018 | $154.58M | +43.8% | 83.6% | 28.1% | 18.5% |
| Dec 2017 | $107.52M | +544.1% | 86.1% | 24.4% | -85.1% |
| Dec 2016 | $16.69M | N/A | 70.5% | -72.7% | -110.5% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income rose 197.1% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $376.13M | $297.20M | $245.32M | $205.62M | $198.87M | $212.17M | $189.39M | $154.58M | $107.52M | $16.69M |
| Cost of revenue | $45.50M | $35.40M | $25.21M | $17.56M | $21.14M | $23.54M | $23.93M | $25.37M | $14.93M | $4.93M |
| Gross profit | $330.63M | $261.80M | $220.10M | $188.06M | $177.73M | $188.63M | $165.46M | $129.20M | $92.59M | $11.77M |
| Research and development | $100.37M | $83.15M | $68.91M | $52.53M | $70.37M | $38.52M | $31.79M | $33.04M | $22.38M | $16.18M |
| Operating income | $20.88M | -$3.67M | -$22.29M | $9.86M | $19.01M | $76.26M | $68.25M | $43.46M | $26.29M | -$12.14M |
| Net income | $2.85M | -$11.84M | -$10.55M | $13.67M | $16.00M | $37.75M | $40.56M | $28.59M | -$91.47M | -$18.44M |
| EBITDA | $34.78M | $16.32M | $9.88M | $33.53M | $48.78M | N/A | $71.46M | N/A | N/A | N/A |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $117.56M | $90.21M | $72.45M | $106.50M | $97.29M | $93.22M | $79.09M | $92.70B | $74.85M | $74.09M | $55.59M | $81.87M |
| Gross profit | $102.19M | $75.67M | $65.80M | $85.40M | $90.22M | $84.25M | $70.77M | $80.50B | $68.03M | $66.11M | $47.20M | $74.71M |
| Operating income | $29.89M | -$111.00K | -$5.29M | $2.00M | $15.75M | $9.00M | -$7.43M | $6.60B | $3.33M | -$3.12M | -$16.31M | $604.93K |
| Net income | $22.43M | $1.64M | -$5.21M | $5.30M | $7.55M | $4.69M | -$14.72M | $2.90B | -$1.03M | -$1.22M | -$12.45M | -$2.72M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $101.42M by $44.60M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $499.81M | $414.18M | $462.85M | $425.80M | $450.44M | $342.55M | $255.91M | $214.48M | $199.38M | $133.34M |
| Current assets | $299.38M | $288.32M | $316.34M | $277.50M | $282.80M | $215.47M | $119.44M | $115.44M | $105.87M | $65.41M |
| Cash and equivalents | $146.02M | $56.89M | $61.74M | $207.34M | $217.59M | $167.94M | $74.35M | $80.31M | $70.37M | $33.54M |
| Total liabilities | $222.79M | $185.27M | $244.07M | $221.16M | $231.73M | $192.39M | $138.53M | $152.73M | $176.82M | $104.45M |
| Short-term debt | $8.71M | $7.45M | $5.44M | $5.23M | $4.87M | $3.28M | $53.31M | $40.61M | $22.66M | $26.40M |
| Long-term debt | $92.72M | $78.15M | $136.60M | $131.62M | $122.65M | $121.93M | $0 | $37.27M | $58.68M | N/A |
| Shareholder equity | $277.02M | $228.91M | $218.78M | $204.64M | $218.71M | $150.16M | $117.39M | $61.75M | $16.11M | $27.47M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $496.64M | $467.98M | $489.37M | $499.81M | $403.57M | $446.26M | $403.18M | $399.99M | $425.51M | $388.27M | $409.29M | $461.42M |
| Total liabilities | $205.40M | $197.49M | $220.41M | $222.79M | $178.15M | $206.71M | $187.89M | $178.92M | $199.72M | $182.02M | $218.44M | $242.24M |
| Cash and equivalents | $189.56M | $158.28M | $53.10M | $146.02M | $112.75M | $94.82M | $60.09M | $54.94M | $60.66M | $44.01M | $48.09M | $61.74M |
| Shareholder equity | $291.24M | $270.49M | $268.96M | $277.02M | $225.42M | $239.55M | $214.00M | $221.06M | $225.79M | $206.24M | $190.85M | $219.19M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 98.6% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $54.71M | -$1.79M | -$17.30M | $22.46M | $37.84M | $83.63M | $74.15M | $46.34M | $45.84M | -$10.52M |
| Capital expenditures | $755.00K | $796.00K | $1.46M | $1.98M | $16.72M | $15.30M | $25.45M | $4.31M | $7.25M | $1.59M |
| Free cash flow | $53.95M | -$2.59M | -$18.77M | $20.48M | $21.13M | $68.33M | $48.70M | $42.03M | $38.59M | -$12.11M |
| Investing cash flow | $26.25M | $31.62M | -$129.39M | $5.32M | -$21.30M | -$15.63M | -$28.26M | -$4.31M | -$7.25M | -$60.45M |
| Financing cash flow | $1.50M | -$34.41M | -$1.04M | -$4.98M | -$27.95M | $60.69M | -$63.47M | -$20.55M | -$3.91M | $70.81M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $32.55M | -$12.68M | $1.95M | $10.71M | $32.03M | $11.74M | $232.00K | $9.33M | $9.74M | -$13.22M | -$7.65M | $12.18M |
| Capital expenditures | $279.95K | $82.45K | $238.00K | $269.00K | $70.00K | $128.00K | $288.00K | $136.00K | $366.00K | $214.00K | $80.00K | $331.44K |
| Free cash flow | $32.27M | -$12.77M | $1.71M | $10.44M | $31.96M | $11.62M | -$56.00K | $9.20M | $9.38M | -$13.44M | -$7.73M | $11.85M |
Frequently Asked Questions About PHAR
What is Pharming Group NV's annual revenue?
Pharming Group NV reported revenue of $376.13M for the fiscal year ended Dec 31, 2025.
How fast is Pharming Group NV's revenue growing?
Revenue was up 26.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 22.3%.
Is Pharming Group NV profitable?
Yes. Pharming Group NV reported net income of $2.85M for the fiscal year ended Dec 31, 2025, with a net margin of 0.8%.
How much free cash flow does PHAR generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $54.71M minus capital expenditures of $755.00K produced free cash flow of $53.95M.
How much debt does Pharming Group NV have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $92.72M, short-term debt of $8.71M and cash and equivalents of $146.02M.
PHAR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors